( January 5, 2026, 9:08 AM EST) -- NEWARK, N.J. — An aesthetic medical practice facing allegations that it improperly marketed and sold compounded drug products that purport to contain semaglutide XE "semaglutide" lost its bid to dismiss a complaint filed by the manufacturer of Ozempic, Wegovy and Rybelsus, with a New Jersey federal judge finding that the manufacturer has standing and stated a claim and that the allegations are not preempted by federal law....